Virtus ETF Advisers’s ADMA Biologics ADMA Stock Holding History

Virtus ETF Advisers’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$154K	Hold	18,412	–	–	0.06%	318
2026 Q1	$166K	Hold	18,412	–	–	0.08%	269
2025 Q4	$336K	Hold	18,412	–	–	0.16%	158
2025 Q3	$270K	Hold	18,412	–	–	0.15%	178
2025 Q2	$335K	Hold	18,412	–	–	0.2%	135
2025 Q1	$365K	Sell	18,412 -316	-2%	-$5.46K	0.24%	128
2024 Q4	$321K	Sell	18,728 -11,824	-39%	-$222K	0.13%	236
2024 Q3	$611K	Hold	30,552	–	–	0.29%	177
2024 Q2	$342K	Sell	30,552 -63,760	-68%	-$535K	0.17%	202
2024 Q1	$622K	Buy	94,312 +13,569	+17%	+$74.2K	0.33%	155
2023 Q4	$365K	Buy	80,743 +2,519	+3%	+$9.32K	0.23%	180
2023 Q3	$280K	Sell	78,224 -10,111	-11%	-$38.9K	0.17%	208
2023 Q2	$326K	Buy	88,335 +4,410	+5%	+$16.3K	0.19%	180
2023 Q1	$278K	Buy	83,925 +1,486	+2%	+$5.14K	0.15%	256
2022 Q4	$320K	Buy	+82,439	New	+$254K	0.17%	240

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Virtus ETF Advisers's ADMA Position: Q2 2026 in Review

Virtus ETF Advisers held its ADMA Biologics (ADMA) position steady in Q2 2026 at 18,412 shares worth $154K. The position accounts for 0.06% of the portfolio, ranked #318.

Virtus ETF Advisers first reported a position in ADMA in Q4 2022 and has held it in 15 quarters since. The position peaked at $622K in Q1 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Virtus ETF Advisers held 18,412 shares of ADMA Biologics worth $154K as of Q2 2026.
Virtus ETF Advisers left its ADMA Biologics share count unchanged in Q2 2026.
ADMA Biologics made up 0.06% of Virtus ETF Advisers's portfolio in Q2 2026, its #318 holding.
Virtus ETF Advisers first reported a position in ADMA Biologics in Q4 2022 and has held it in 15 quarters since.
Virtus ETF Advisers's ADMA Biologics position peaked at $622K in Q1 2024.
322 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Virtus ETF Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.